When a worn joint is also an inflamed one

For many patients with advanced joint disease, the problem is not wear alone. The joint aches, stiffens overnight, then flares — swelling that settles slowly and returns unpredictably. When that pattern becomes familiar, it usually signals two processes running in parallel: progressive cartilage surface loss and persistent synovial inflammation. The two are not independent. Degraded cartilage releases breakdown products into the joint space, priming the synovium to produce inflammatory mediators; those mediators, in turn, accelerate cartilage breakdown further. Each side of the cycle sustains the other.

Most single-agent injections are designed to interrupt one side of that cycle. Regenerative scaffolds work on the articular surface; anti-inflammatory or viscosupplementing agents target the joint environment. Used alone, either approach leaves the other problem unaddressed.

CFI+ is a dual-injection framework designed specifically for joints that are both worn and reactive — allocating one agent (ChondroFiller injection) to the articular surface and another (Arthrosamid) to the synovial layer, both delivered in a single outpatient visit.

ChondroFiller injection: rebuilding the articular surface

ChondroFiller injection is a Type I collagen scaffold — acellular, murine-derived, and acid-extracted — that arrives as a liquid and gels within minutes of being placed in the joint. The in-situ polymerisation creates a stable, three-dimensional matrix directly over the worn articular surface; no pre-formed implant is fitted, and no donor cells are introduced.

The repair mechanism is acellular matrix-induced chondrogenesis. Once the scaffold is in place, resident progenitor cells from the surrounding tissue migrate in, mature into chondrocyte-like cells, and begin depositing new matrix. The collagen scaffold then resorbs progressively, leaving behind tissue generated by the patient's own biology. That sequence — recruit, differentiate, build, resorb — is what makes ChondroFiller injection a regenerative pathway rather than a permanent filler.

As a CE-marked Class III medical device, it is delivered as an ultrasound-guided outpatient injection, not as an arthroscopic or operating-theatre procedure. Within the CFI+ protocol, 2.3 mL is applied as a resorbable cushion over the bone-end surfaces — the articular layer that bears direct load and is most exposed to wear.

Published outcome data, drawn from both manufacturer-sponsored and independent investigations, show IKDC scores improving by approximately 30 points over one to two years in the knee. The injection is designed to address structural loss at the articular interface: the surface layer where cartilage thinning and bone exposure concentrate the greatest mechanical stress.

Arthrosamid: protecting the joint environment

Arthrosamid occupies an entirely different functional role from ChondroFiller injection — and the distinction is worth stating plainly. It is not a regenerative therapy. It does not recruit cells, deposit new matrix, or resorb. Arthrosamid (iPAAG) is a permanent structural hydrogel: 97.5% water and 2.5% cross-linked polyacrylamide, manufactured by Contura Orthopaedics as a single 6 mL injection. Once in the joint, it does not break down.

The integration process is well-characterised in animal histopathology. Within 10–14 days of injection, synovial cells begin proliferating and invading the gel. By day 30 in horses and day 90 in rabbits, this activity produces a stable sub-synovial layer — a bed of gel traversed by vascularised connective tissue and covered by a neo-synovial lining facing the joint cavity. The scientific literature classifies this as a low-level macrophage-driven foreign body response: the body accepts the hydrogel by encapsulating it within its own tissue rather than absorbing it. In equine joints, this structure has been shown to persist for up to two years post-injection. Patients are better placed when they understand that permanence and its mechanism before proceeding, rather than encountering it as a surprise.

The settled sub-synovial layer appears to serve two functions: viscoelastic cushioning — absorbing and distributing mechanical load — and modulation of the inflammatory joint environment. A published case series by Maulana, Cole, and Lee (Journal of Arthritis, 2022) found reduction in patellofemoral bone marrow lesions following a single injection, suggesting an effect beyond simple mechanical padding.

Real-world clinical data support that picture. An independent, clinician-led study of 269 patients and 314 knees showed sustained improvement in pain (VAS), function (Oxford Knee Score), and performance (Lysholm Score) for up to two years, with better outcomes in older adults with mild-to-moderate OA who did not have diabetes. A £150,000 NHS-funded mechanistic study at the Robert Jones and Agnes Hunt Orthopaedic Hospital, under way since September 2023, is working to clarify the precise pathways involved and identify which patient profiles respond best.

Why two agents cover ground one cannot

The synergy argument rests on a biological feedback loop that the previous sections have laid out: synovitis generates enzymes and cytokines that degrade newly forming matrix, while surface loss sustains the mechanical irritation that keeps inflammation lit. Treating one side without the other leaves either the repair environment hostile or the structural layer unaddressed. CFI+ is designed to interrupt both sides of that cycle in a single visit — not by combining two agents that do the same thing, but by applying each to the distinct anatomical layer it is best suited to reach.

The clinical rationale, however, is mechanistic rather than proven in combination. Each agent is supported by its own independent evidence base, but no prospective study has evaluated ChondroFiller injection and Arthrosamid as a paired treatment, and no combination-specific randomised controlled trial has been published. The inference that acting on both layers simultaneously may produce a better outcome than acting on one alone is biologically coherent, but it remains an extrapolation from individual-agent data rather than a demonstrated effect of the combination itself.

One further question is openly unresolved: whether concurrent injection is preferable to a staged approach — calming the joint environment first, then placing the collagen scaffold once synovitis has settled. Staging might theoretically create more favourable conditions for cell migration into the CFI scaffold; concurrent delivery is more convenient and is the current CFI+ protocol. Neither approach has been formally compared. Patients considering CFI+ should understand this is a live clinical uncertainty, not a settled sequencing decision.

Who CFI+ is most likely to suit

The typical CFI+ candidate presents with two concurrent problems: structural loss at the articular surface and a joint that has become persistently reactive — regular flares, background swelling, or confirmed synovitis on imaging. Either problem alone might point to a single-agent pathway; both together are what frames the combination as appropriate.

Advanced wear is not a barrier to treatment. The injectable scaffold pathway extends the addressable indication to diffuse cartilage loss, including Kellgren-Lawrence Grade IV, because the injection is placed top-down into a fluid joint rather than requiring surgical containment within a prepared defect. Patients who have been told they are 'too worn' for regenerative treatment may find they remain candidates via this route.

The two agents are not automatically paired. A joint that is structurally worn but not especially reactive may suit ChondroFiller injection alone; one that is inflamed but retains reasonable surface integrity might warrant Arthrosamid without the scaffold component. CFI+ is reserved for the overlap between the two.

The Arthrosamid real-world data described in the previous section — better outcomes in older adults with mild-to-moderate OA who did not have diabetes — offer useful context for understanding which patients within that broader worn-and-reactive group tend to respond most consistently. Whether that profile modifies combination candidacy is one of several questions a clinical assessment is better placed to answer than any self-selection checklist.

Suitability for CFI+ depends on factors including synovial reactivity, remaining cartilage architecture, and metabolic history — none of which can be resolved from a patient history alone. Imaging and clinical examination are required, and no two joints age in an identical way.

Getting assessed at London Cartilage Clinic

CFI+ is delivered as a day-case dual injection at London Cartilage Clinic on Harley Street — ChondroFiller injection (2.3 mL) placed over the worn bone surfaces, followed by Arthrosamid (6 mL) into the sub-synovial space, both under ultrasound guidance in an outpatient setting. No theatre time or general anaesthesia is required. The guide cost for the standard CFI+ combination is £6,000; a Tri-Active upgrade co-delivering autologous mesenchymal stem cells is priced at £11,000 — confirm current pricing at consultation, as individual treatment planning may affect the final figure.

Professor Paul Y. F. Lee leads Liquid Cartilage™ delivery in the UK at London Cartilage Clinic. Technique precision in image-guided scaffold placement is a meaningful factor in outcomes, not a peripheral procedural detail. Appointments and clinical assessment are available via londoncartilage.com.

One question worth raising at that assessment is the permanence of the Arthrosamid sub-synovial layer. The hydrogel integrates into the joint lining and does not resorb; while this does not prevent future joint replacement, surgeons planning arthroplasty will need to know the gel is present and should be informed at pre-operative assessment. For most patients this is a practical consideration rather than a barrier — but it belongs in the informed-consent conversation now rather than as a discovery later.